Condition: AML - Acute Myeloid Leukemia · AML With Mutated NPM1 · AML, Adult Recurrent · Sponsor: BlueSphere Bio, Inc
The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.
This description comes directly from the study's public registry record.
Medical Director: Nawazish Khan, BlueSphere Bio, MD · 252-347-4938 · nkhan@bluespherebio.com
Always discuss trial participation with your own doctor first.
| Washington University at St Louis | St Louis, Missouri, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07566585